License Agreement Sample Contracts

Share Cite Term
Link

Embed (HTML)
Vascular Biogenics Ltd. – Crucell Holland B.V. - Vascular Bio Genics Ltd. Commercial Gene Therapy License Agreement (October 11th, 2017)

This Commercial Gene Therapy License Agreement ("Agreement") is made and entered into on April 15, 2011 ("EFFECTIVE DATE") by and between:

Spero Therapeutics, Inc. – CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENT BY AND BETWEEN MEIJI SEIKA PHARMA CO., LTD. AND SPERO OPCO, INC. Portions of This Exhibit, Indicated by the Mark [***], Were Omitted and Have Been Filed Separately With the Securities and Exchange Commission Pursuant to the Registrants Application Requesting Confidential Treatment Pursuant to Rule 406 of the Securities Act of 1933, as Amended. (October 6th, 2017)

This License Agreement (this Agreement) is made and effective as of the 14th day of June, 2017 (the Effective Date) by and between Meiji Seika Pharma Co., Ltd., a Japanese corporation with offices at 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002 Japan (Meiji) and Spero OpCo, Inc., a Delaware corporation with offices at 675 Massachusetts Avenue, 14th Floor, Cambridge, MA 20139, USA (Spero).

Allena Pharmaceuticals, Inc. – License Agreement (October 6th, 2017)

This License Agreement (this Agreement) is entered into as of the 22 day of March 2012 (the Effective Date) by and between Althea Technologies, Inc., a Delaware corporation with its principal place of business at 11040 Roselle Street, San Diego, CA 92121 (Althea), and Allena Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at One Newton Executive Park, Suite 202, Newton, MA 02462 (Allena).

Gateway Inds Inc – License Agreement (October 2nd, 2017)

This License Agreement (the "Agreement") is entered into as of September 27, 2017 (the "Effective Date") by and between Function(x) Inc., with its principal place of business at 902 Broadway, 11th Floor, New York, NY 10010 ("Fn(x)"), and Bump Digital LLC, with its principal place of business at [_________________________________] ("Bump").

Allena Pharmaceuticals, Inc. – License Agreement (September 28th, 2017)

This License Agreement (this Agreement) is entered into as of the 22 day of March 2012 (the Effective Date) by and between Althea Technologies, Inc., a Delaware corporation with its principal place of business at 11040 Roselle Street, San Diego, CA 92121 (Althea), and Allena Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at One Newton Executive Park, Suite 202, Newton, MA 02462 (Allena).

Rhythm Pharmaceuticals, Inc. – License Agreement by and Between Camurus Ab and Rhythm Pharmaceuticals, Inc. (September 25th, 2017)

This License Agreement is made as off the Effective Date (hereinafter defined) between Camurus AB, a limited liability company organized and existing under the laws of Sweden and having its principal place of business at Ideon Science Park, Solvegatan 41, SE-223 70 Lund, Sweden (Camurus) and Rhythm Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware and having its principal place of business at 855 Boylston Street, 11th Floor, Boston, MA 02116 USA (Rhythm) (each a Party and collectively, the Parties)

Switch, Inc. – Exhibit A-1 Project Exhibit A-2 Complex Exhibit A-3 Building Exhibit B Premises Exhibit C Tenant Improvement Process and Procedure Exhibit D Rules and Regulations Exhibit E Master Sign Plan Exhibit F Parking Exhibit G Suite License Agreement Exhibit H Intentionall Omitted Exhibit I Renewal Options Exhibit J Intentionall Omitted Exhibit K Intentionall Omitted Exhibit L Subordination and Non-Disturbance Agreement Exhibit M Master Lease (September 25th, 2017)

THIS LEASE AGREEMENT (Lease), dated November 4, 2010, made by and between Beltway Business Park Office No. 1, LLC, a Nevada limited liability company, (Landlord) and Switch Communication Group L.L.C., a Nevada limited liability company, (Tenant), and constitutes a lease between the parties of the Premises as identified in Section 1.1 hereof on the terms and conditions and with and subject to the covenants and agreements of the parties hereinafter set forth below. The Premises are located within the Building and Project described in Sections 1.3 and 1.4. The Tenant acknowledges and agrees that it is intended that this is a net lease.

Spero Therapeutics, Inc. – CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENT BY AND BETWEEN MEIJI SEIKA PHARMA CO., LTD. AND SPERO OPCO, INC. Portions of This Exhibit, Indicated by the Mark [***], Were Omitted and Have Been Filed Separately With the Securities and Exchange Commission Pursuant to the Registrants Application Requesting Confidential Treatment Pursuant to Rule 406 of the Securities Act of 1933, as Amended. (September 22nd, 2017)

This License Agreement (this Agreement) is made and effective as of the 14th day of June, 2017 (the Effective Date) by and between Meiji Seika Pharma Co., Ltd., a Japanese corporation with offices at 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002 Japan (Meiji) and Spero OpCo, Inc., a Delaware corporation with offices at 675 Massachusetts Avenue, 14th Floor, Cambridge, MA 20139, USA (Spero).

Restoration Robotics Inc – Confidential Portions of This Exhibit Marked as [***] Have Been Omitted Pursuant to a Request for Confidential Treatment and Have Been Filed Separately With the Securities and Exchange Commission. FIRST AMENDMENT TO HARRIS/HSC LICENSE AGREEMENT (September 22nd, 2017)

This First Amendment to Harris/HSC License Agreement between Restoration Robotics, Inc., James A. Harris, MD and HSC Development LLC (the First Amendment to License Agreement) is made effective as of January 5, 2009 (the Effective Date of the First Amendment to License Agreement).

RISE Education Cayman Ltd – Form of License Agreement (September 22nd, 2017)

This License Agreement (this Agreement) is entered into as of [ ] (the Effective Date) by and between Rise (Tianjin) Education Information Consulting Company Limited (Rui Si (Tian Jin )Jiao Yu Xin Xi Zi Xun You Xian Gong Si ) (Licensor) and [ ] (Licensee). Licensor or Licensee are referred to individually as a Party and, collectively, as the Parties.

Restoration Robotics Inc – Confidential Portions of This Exhibit Marked as [***] Have Been Omitted Pursuant to a Request for Confidential Treatment and Have Been Filed Separately With the Securities and Exchange Commission. SECOND AMENDMENT TO HARRIS/HSC LICENSE AGREEMENT (September 22nd, 2017)

This Second Amendment to Harris/HSC License Agreement between Restoration Robotics, Inc., James A. Harris, M.D. and HSC Development LLC (the Second Amendment to License Agreement) is made effective as of February 23, 2015.

Restoration Robotics Inc – Confidential Portions of This Exhibit Marked as [***] Have Been Omitted Pursuant to a Request for Confidential Treatment and Have Been Filed Separately With the Securities and Exchange Commission. LICENSE AGREEMENT (September 22nd, 2017)

THIS LICENSE AGREEMENT (License Agreement) is made and entered as of July 25, 2006 (Effective Date), between Restoration Robotics, Inc., a Delaware corporation having a place of business at 1383 Shore Bird Way, Mountain View, CA 94043 (Restoration), HSC Development LLC, a Delaware limited liability company having a place of business at 3003 E. Third Avenue, Suite 201, Denver, CO 80206 (HSC), and James A. Harris, MD, an individual having an address of [***] (Harris), each referred to herein as a Party and collectively as the Parties.

Ameri Metro, Inc. (formerly Yellowwood) – Opportunity License Agreement Ameri Metro, Inc (September 21st, 2017)

This Opportunity License Agreement is established this 24 day of May 2012 buy and between And Ameri Metro, Inc. hereinafter called party A

OptiNose, Inc. – LICENSE AGREEMENT Between OPTINOSE AS and AVANIR PHARMACEUTICALS, INC. LICENSE AGREEMENT (September 18th, 2017)

This LICENSE AGREEMENT (the Agreement) is entered into on July 1, 2013 (the Effective Date) between OptiNose AS, a Norwegian corporation, company registration number 982483131, with its principal place of business at Austliveien 1, 0751 Oslo, Norway, and its postal address at Pb 288 Roa, 0702 Oslo, Norway (OptiNose), and Avanir Pharmaceuticals, Inc., a Delaware corporation, with offices at 20 Enterprise, Suite 200, Aliso Viejo, CA 92656, U.S.A. (Avanir). OptiNose and Avanir are sometimes referred to herein individually as a Party and collectively as the Parties.

RISE Education Cayman Ltd – Form of License Agreement (September 15th, 2017)

This License Agreement (this Agreement) is entered into as of [ ] (the Effective Date) by and between Rise (Tianjin) Education Information Consulting Company Limited ( ) (Licensor) and [ ] (Licensee). Licensor or Licensee are referred to individually as a Party and, collectively, as the Parties.

Bookedbyus Inc. – License Agreement (September 15th, 2017)
Quantech Electronics Corp – Assignment of License Agreement (September 8th, 2017)

This Assignment of License Agreement (this "Assignment Agreement") is entered into as of September 6, 2017 (the "Effective Date"), by and between PalliaTech, Inc., a Delaware corporation, and PhytaTech CO, LLC (collectively referred to herein as the "Assignor"), and EVIO, Inc., a Colorado corporation (the "Assignee"). Capitalized terms used but not defined herein shall have the meanings ascribed to them in that certain Transfer Agreement, dated as of the date hereof (as it may be amended in accordance with its terms, the "Transfer Agreement"), by and between the Assignor and the Assignee. The Assignor and the Assignee are sometimes referred to individually in this Assignment Agreement as a "party" and collectively as the "parties".

Adial Pharmaceuticals, L.L.C. – Amendment #2 to License Agreement (September 7th, 2017)

This Amendment #1, dated as of May 18, 2016 (this "Agreement"), to the Original License Agreement (as defined below) is by and between the University of Virginia Patent Foundation d/b/a the University of Virginia Licensing and Ventures Group, a Virginia not-for-profit corporation of the Commonwealth of Virginia, having its principal offices at 250 West Main Street, Charlottesville, VA 29902 ("UVA LVG"), and ADial Pharmaceuticals, LLC, a Virginia limited liability company ("Adial" and together with "UVA LVG", the "Parties").

Adial Pharmaceuticals, L.L.C. – Amendment #4 to License Agreement (September 7th, 2017)

This Amendment #4, dated as of August 15, 2017 (this "Agreement"), to the Original License Agreement (as defined below) is by and between the University of Virginia Patent Foundation d/b/a the University of Virginia Licensing and Ventures Group, a Virginia not-for-profit corporation of the Commonwealth of Virginia, having its principal offices at 722 Preston Avenue, Suite 107, Charlottesville, VA 29903 ("UVA LVG"), and ADial Pharmaceuticals, LLC, a Virginia limited liability company ("Adial" and together with "UVA LVG", the "Parties").

Adial Pharmaceuticals, L.L.C. – Adial/Uvapf License Agreement (September 7th, 2017)

This Agreement is entered into and made effective as of January 21, 2011 (the "Effective Date") by and between the University of Virginia Patent Foundation ("Foundation"), a not-for-profit corporation of the Commonwealth of Virginia having its principal offices at 250 West Main Street, Charlottesville, VA, 29902; and ADial Pharmaceuticals, L.L.C. ("Adial"), a Virginia limited liability company having its principal offices at 1001 Research Park Drive, Suite 100, Charlottesville, VA 22911.

Adial Pharmaceuticals, L.L.C. – Amendment #1 to License Agreement (September 7th, 2017)

This Amendment #1, dated as of October 21, 2013 (this "Agreement"), to the Original License Agreement (as defined below) is by and between the University of Virginia Patent Foundation d/b/a the University of Virginia Licensing and Ventures Group, a Virginia not-for-profit corporation of the Commonwealth of Virginia, having its principal offices at 250 West Main Street, Charlottesville, VA 29902 ("UVA LVG"), and ADial Pharmaceuticals, LLC, a Virginia limited liability company ("Adial" and together with "UVA LVG", the "Parties").

RISE Education Cayman Ltd – Form of License Agreement (September 6th, 2017)

This License Agreement (this Agreement) is entered into as of [ ] (the Effective Date) by and between Rise (Tianjin) Education Information Consulting Company Limited ( ) (Licensor) and [ ] (Licensee). Licensor or Licensee are referred to individually as a Party and, collectively, as the Parties.

Restoration Robotics Inc – Confidential Portions of This Exhibit Marked as [***] Have Been Omitted Pursuant to a Request for Confidential Treatment and Have Been Filed Separately With the Securities and Exchange Commission. FIRST AMENDMENT TO HARRIS/HSC LICENSE AGREEMENT (September 1st, 2017)

This First Amendment to Harris/HSC License Agreement between Restoration Robotics, Inc., James A. Harris, MD and HSC Development LLC (the First Amendment to License Agreement) is made effective as of January 5, 2009 (the Effective Date of the First Amendment to License Agreement).

Restoration Robotics Inc – Confidential Portions of This Exhibit Marked as [***] Have Been Omitted Pursuant to a Request for Confidential Treatment and Have Been Filed Separately With the Securities and Exchange Commission. SECOND AMENDMENT TO HARRIS/HSC LICENSE AGREEMENT (September 1st, 2017)

This Second Amendment to Harris/HSC License Agreement between Restoration Robotics, Inc., James A. Harris, M.D. and HSC Development LLC (the Second Amendment to License Agreement) is made effective as of February 23, 2015.

Restoration Robotics Inc – Confidential Portions of This Exhibit Marked as [***] Have Been Omitted Pursuant to a Request for Confidential Treatment and Have Been Filed Separately With the Securities and Exchange Commission. LICENSE AGREEMENT (September 1st, 2017)

THIS LICENSE AGREEMENT (License Agreement) is made and entered as of July 25, 2006 (Effective Date), between Restoration Robotics, Inc., a Delaware corporation having a place of business at 1383 Shore Bird Way, Mountain View, CA 94043 (Restoration), HSC Development LLC, a Delaware limited liability company having a place of business at 3003 E. Third Avenue, Suite 201, Denver, CO 80206 (HSC), and James A. Harris, MD, an individual having an address of [***] (Harris), each referred to herein as a Party and collectively as the Parties.

OptiNose, Inc. – LICENSE AGREEMENT Between OPTINOSE AS and AVANIR PHARMACEUTICALS, INC. LICENSE AGREEMENT (August 31st, 2017)

This LICENSE AGREEMENT (the Agreement) is entered into on July 1, 2013 (the Effective Date) between OptiNose AS, a Norwegian corporation, company registration number 982483131, with its principal place of business at Austliveien 1, 0751 Oslo, Norway, and its postal address at Pb 288 Roa, 0702 Oslo, Norway (OptiNose), and Avanir Pharmaceuticals, Inc., a Delaware corporation, with offices at 20 Enterprise, Suite 200, Aliso Viejo, CA 92656, U.S.A. (Avanir). OptiNose and Avanir are sometimes referred to herein individually as a Party and collectively as the Parties.

GraniteShares Gold Trust – License Agreement (August 25th, 2017)

THIS LICENSE AGREEMENT (this "Agreement") is entered into effective as of the 3rd day of July, 2017 (the "Effective Date"), by and between The Bank of New York Mellon, a New York banking corporation ("Licensor"), and GraniteShares LLC, a Delaware limited liability company, as sponsor to Licensed Products as defined below ("Licensee").

MassRoots, Inc. – License Agreement (August 24th, 2017)

THIS LICENSE AGREEMENT (this "Agreement"), made and entered into this 23 day of August, 2017, is by and between MASSROOTS, INC., a Delaware corporation, ("MassRoots") and REGS TECHNOLOGY, LLC, a Colorado limited lability company ("Company"). MassRoots and Company may also be referred to in this Agreement individually as a "Party" or collectively as the "Parties".

Smsa Ballinger Acquisition Corp – License Agreement (August 14th, 2017)

This License Agreement (this "Agreement") is made and entered into on August 9, 2017, by and between Blackboxstocks Inc. ("Blackbox"), a Nevada corporation and EIGH8T TECHNOLOGIES INC also known as Black Box Traders (referred to herein as "BBTR"), a British Virgin Island registered company. Blackbox and BBTR are each hereinafter referred to individually as a "Party" and collectively as the "Parties."

AB Private Credit Investors Corp – License Agreement (August 14th, 2017)

This LICENSE AGREEMENT (this Agreement) is made and effective as of August 14, 2017 (the Effective Date) by and between AB Private Credit Investors LLC (the Licensor), a Delaware limited liability company, and AB Private Credit Investors Corporation, a Maryland corporation (the Licensee) (each a party, and collectively, the parties).

Titan Computer Services Inc. – LICENSE AGREEMENT Between ALTITUDE INTERNATIONAL INC. And SPORTING EDGE UK LTD., INC. (August 14th, 2017)

This License Agreement ("Agreement"), effective as of June 27, 2017 (the "Effective Date"), is by and between Sporting Edge UK Ltd., Inc., a UK company located at Unit J, Loddon Business Centre, Roentgen Road, Basingstoke, RG24 8NG, UK ("Licensor"), and Altitude International, Inc., a Wisconsin corporation located at 515 E. Las Olas Blvd. #120, Ft. Lauderdale, FL 33301 ("Licensee").

Fulgent Diagnostics, Inc. – Technical Know-How License Agreement Between Fulgent Genetics, Inc. And Fujian Fulgent Gene Biotech Co., Ltd. No.: FULGENT201611-9 Date: April 25, 2017 (August 14th, 2017)

This Technical Know-how License Agreement (hereinafter referred to as "this Agreement") is concluded by the following parties in Shenzhen, the People's Republic of China (hereinafter "PRC") on April 25, 2017:

Oxis International – License Agreement (August 11th, 2017)

THIS LICENSE AGREEMENT (the "Agreement") dated as of December 31, 2014 (the "Effective Date"), is entered into between ID4 Pharma, LLC ("ID4"), a having a place of business at 1654 Settlers Drive, Sewickley, PA 15143, and Oxis Biotech, Inc., a Delaware corporation ("Company"), having a place of business at 1402 North Beverly Drive, Beverly Hills, CA 90210 .

Oxis International – License Agreement (August 11th, 2017)

THIS LICENSE AGREEMENT (this "Agreement") dated as of September 3, 2015 (the "Effective Date"), is entered into between Daniel A. Vallera, an individual having a place of residence at ____________________________________ , Jeffrey Lion, an individual having a place of residence at ____________________________________ (collectively hereinafter "Licensor"), and Oxis Biotech, Inc., a Delaware corporation ("Company" or "Oxis"), having a place of business at 1402 North Beverly Drive, Beverly Hills, CA 90210 .

Recro Pharma, Inc. – License Agreement (August 11th, 2017)

This agreement ("Agreement") is made by and between Recro Pharma, Inc., a Pennsylvania corporation having an address at 490 Lapp Road, Malvern PA 19355 ("Licensee"), and Cornell University ("University") as represented by its Center for Technology Licensing ("CTL") at Cornell University at 395 Pine Tree Road, Ithaca, NY 14850 (University, CTL and CRF (as defined below) collectively "Cornell" and each of Licensee and Cornell a "Party" and collectively, the "Parties").